Myomo® Announces New Sales and Service Agreement for Chile
April 16 2019 - 8:00AM
Business Wire
Tecnoplanta Expands its Portfolio with
MyoPro®
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a
wearable medical robotics company that offers increased
functionality for those suffering from neurological disorders and
upper limb paralysis, today announced that it has signed an
agreement with Tecnoplanta Orthopedic Laboratory with the goal of
offering MyoPro in Chile.
With over 20 years of operation, Tecnoplanta Orthopedic
Laboratory is dedicated to providing services in both orthoses and
prostheses for people who have suffered strokes, amputations or
musculoskeletal malformations, providing patients with high quality
products of advanced technology. Tecnoplanta serves patients in
Chile and across Latin America.
Mario Campos, Tecnoplanta Chief Product Officer, Chief
Innovation Officer, Chief Orthotics and Prosthetics Technician
explains, “Our vision is to be an orthopedic laboratory recognized
by health organizations throughout Chile as providing a high
quality and efficient service responding to the demands of a
globalized, changing and competitive world. Our mission is to
deliver high quality care to our patients, committed from the
beginning with their recovery process providing high-tech supplies,
backed by large world-renowned companies in the field of technical
orthopedics, such as Myomo.”
Paul R. Gudonis, Chairman and CEO of Myomo, said, “Since
individuals from around the world are seeking a MyoPro for their
paralyzed arms, this agreement with Tecnoplanta enables Myomo to
assist patients in South America, supplementing our existing
international reach in Canada and Europe. Myomo and Tecnoplanta are
ideal partners, both of us committed to excellence in technology
and patient care.”
About Myomo
Myomo, Inc. is a wearable medical robotics company that offers
expanded mobility for those suffering from neurological disorders
and upper limb paralysis. Myomo develops and markets the MyoPro
product line. MyoPro is a powered upper limb orthosis designed to
support the arm and restore function to the weakened or paralyzed
arms of patients suffering from CVA stroke, brachial plexus injury,
traumatic brain or spinal cord injury, ALS or other neuromuscular
disease or injury. It is currently the only marketed device that,
sensing a patient’s own EMG signals through non-invasive sensors on
the arm, can restore an individual’s ability to perform activities
of daily living, including feeding themselves, carrying objects and
doing household tasks. Many are able to return to work, live
independently and reduce their cost of care. Myomo is headquartered
in Cambridge, Massachusetts, with sales and clinical professionals
across the U.S. and representatives internationally. For more
information, please visit www.myomo.com.
Forward Looking StatementsThis press release contains
forward-looking statements regarding the Company's future business
expectations which are subject to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, but are not limited to, our
plans for offering our MyoPro product in Chile, expansion of our
business to Latin America and beyond. These forward-looking
statements are only predictions and may differ materially from
actual results due to a variety of factors. Our actual results
could differ materially from those anticipated in these forward
looking statements for many reasons, including, without limitation,
risks related to regulatory approval and market acceptance of our
products, our ability to secure and maintain reimbursement for our
products, our ability to obtain additional funding to sustain and
grow our business, and the other risk factors contained in our
filings made with the Securities and Exchange Commission. More
information about factors that potentially could affect Myomo's
business and financial results is included in Myomo's filings with
the Securities and Exchange Commission. The Company cautions
readers not to place undue reliance on any such forward-looking
statements, which speak only as of the date made. The Company
disclaims any obligation subsequently to revise any forward-looking
statements to reflect events or circumstances after the date of
such statements or to reflect the occurrence of anticipated or
unanticipated events.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190416005039/en/
Investor Relations:Vivian CervantesPCG
Advisory646-863-6274vivian@pcgadvisory.comPublic
Relations:Sarah KarrMatter
Communications978-518-4817myomo@matternow.com
Myomo (AMEX:MYO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Myomo (AMEX:MYO)
Historical Stock Chart
From Apr 2023 to Apr 2024